Erythropoietin therapy for treating anaemia among haemodialysis patients: associations with survival and comparison of treatment strategies
促红细胞生成素治疗血液透析患者贫血:与生存的关系及治疗策略的比较
基本信息
- 批准号:MR/K021699/1
- 负责人:
- 金额:$ 35.64万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Fellowship
- 财政年份:2014
- 资助国家:英国
- 起止时间:2014 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
People with kidney disease are often anaemic, which can reduce their quality of life, with symptoms of fatigue, dizziness, and shortness of breath. Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below normal. The kidneys produce a substance called erythropoietin (EPO) which stimulates the bone marrow to produce red blood cells. Loss of EPO production is a major cause of anaemia in renal failure. Anaemia is measured by blood haemoglobin levels, and can be treated by injections of EPO in drug form. However, at present we do not know enough about the safety of high doses of EPO. This study aims to establish the best use of EPO treatment for patients with chronic kidney disease on haemodialysis, a treatment that takes over the work of the kidneys if they fail. The UK Renal Registry collects data on adults receiving renal replacement therapy from all centres across the UK, and will provide data on patients receiving haemodialysis. Relevant patient information will be extracted from the database, including data on age, sex, disease information, results from blood tests, EPO dose and treatment dates.I will look at haemoglobin levels in patients and EPO dosing over time in the UK, and will compare trends to changes in the UK treatment guidelines. I will see by how much haemoglobin levels differ between people and will examine patterns of repeated haemoglobin levels within individual patients. I will investigate how many people become resistant to EPO therapy. EPO resistance describes patients who fail to reach a haemoglobin target despite a higher than usual dose of EPO, or patients who continuously need a higher dose in order to keep their haemoglobin at a particular level. I will see which factors predict whether people get treated with EPO and examine if EPO treatment is related to the survival of patients. Finally, I will use novel statistical techniques to investigate which strategy for correcting anaemia gives the best survival and the lowest risk of hospitalisation. Findings will be important as they will help clinicians be more aware of the appropriate EPO dosage for haemodialysis patients.
肾病患者通常贫血,这会降低他们的生活质量,并伴有疲劳,头晕和呼吸急促的症状。贫血是循环红细胞的质量和/或数量低于正常的状态。肾脏产生一种叫做促红细胞生成素(EPO)的物质,它刺激骨髓产生红细胞。EPO生产的损失是肾衰竭贫血的主要原因。贫血是通过血液血红蛋白水平来衡量的,可以通过注射药物形式的EPO来治疗。然而,目前我们对高剂量EPO的安全性了解不够。本研究旨在为接受血液透析的慢性肾脏疾病患者确定EPO治疗的最佳用途,如果肾功能衰竭,这种治疗可以接管肾脏的工作。英国肾脏登记研究从英国所有中心收集接受肾脏替代治疗的成人数据,并将提供接受血液透析的患者数据。相关患者信息将从数据库中提取,包括年龄,性别,疾病信息,血液检查结果,EPO剂量和治疗日期等数据。我将研究英国患者的血红蛋白水平和EPO剂量随时间的变化,并将趋势与英国治疗指南的变化进行比较。我将观察人与人之间血红蛋白水平的差异,并将检查个体患者中重复血红蛋白水平的模式。我将调查有多少人对EPO治疗产生耐药性。EPO抵抗是指尽管使用了高于常规剂量的EPO,但仍未能达到血红蛋白目标的患者,或持续需要更高剂量以保持血红蛋白在特定水平的患者。我将看看哪些因素可以预测人们是否接受EPO治疗,并检查EPO治疗是否与患者的生存有关。最后,我将使用新的统计技术来研究哪种纠正贫血的策略可以提供最好的生存率和最低的住院风险。研究结果将是重要的,因为它们将帮助临床医生更清楚地了解血液透析患者的适当EPO剂量。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Predictive models for kidney disease: improving global outcomes (KDIGO) defined acute kidney injury in UK cardiac surgery.
- DOI:10.1186/s13054-014-0606-x
- 发表时间:2014-11-20
- 期刊:
- 影响因子:0
- 作者:Birnie K;Verheyden V;Pagano D;Bhabra M;Tilling K;Sterne JA;Murphy GJ;UK AKI in Cardiac Surgery Collaborators
- 通讯作者:UK AKI in Cardiac Surgery Collaborators
Comparison of two treatment strategies for treating anaemia with erythropoiesis stimulating agent therapy among haemodialysis patients: findings from a marginal structural model
血液透析患者红细胞生成刺激剂治疗贫血的两种治疗策略的比较:边缘结构模型的发现
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Birnie K
- 通讯作者:Birnie K
Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data.
胱抑素 C 用于检测接受恶性肿瘤化疗的儿童肾功能异常的准确性:使用个体患者数据进行的系统评价。
- DOI:10.1007/s00520-017-4002-3
- 发表时间:2018
- 期刊:
- 影响因子:0
- 作者:Whiting P
- 通讯作者:Whiting P
Comparison of microbiological diagnosis of urinary tract infection in young children by routine health service laboratories and a research laboratory: Diagnostic cohort study.
- DOI:10.1371/journal.pone.0171113
- 发表时间:2017
- 期刊:
- 影响因子:3.7
- 作者:Birnie K;Hay AD;Wootton M;Howe R;MacGowan A;Whiting P;Lawton M;Delaney B;Downing H;Dudley J;Hollingworth W;Lisles C;Little P;O'Brien K;Pickles T;Rumsby K;Thomas-Jones E;Van der Voort J;Waldron CA;Harman K;Hood K;Butler CC;Sterne JA
- 通讯作者:Sterne JA
An evaluation of a multi-component adult weight management on referral intervention in a community setting.
- DOI:10.1186/s13104-016-1901-1
- 发表时间:2016-02-17
- 期刊:
- 影响因子:1.8
- 作者:Birnie K;Thomas L;Fleming C;Phillips S;Sterne JA;Donovan JL;Craig J
- 通讯作者:Craig J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kate Birnie其他文献
WCN24-736 INCIDENCE AND CHARACTERISTICS OF HEALTHCARE CLIENTS WITH ACUTE-ON-CHRONIC KIDNEY DISEASE IN THE CITY OF CAPE TOWN, SOUTH AFRICA
- DOI:
10.1016/j.ekir.2024.02.036 - 发表时间:
2024-04-01 - 期刊:
- 影响因子:
- 作者:
Fergus Caskey;Florence Phelanyane;Kate Birnie;Yoav Ben-Shlomo;Ryan Aylward;Brian Rayner;Nicki Tiffin - 通讯作者:
Nicki Tiffin
Life course trajectories of maternal cardiovascular disease risk factors by obstetric history: a UK cohort study using electronic health records
- DOI:
10.1186/s12916-025-03937-y - 发表时间:
2025-02-14 - 期刊:
- 影响因子:8.300
- 作者:
Kate Birnie;Laura D. Howe;Timothy Jones;Paul Madley-Dowd;Florence Z. Martin;Harriet Forbes;Maria Theresa Redaniel;Rosie Cornish;Maria C. Magnus;Neil M. Davies;Kate Tilling;Alun D. Hughes;Deborah A. Lawlor;Abigail Fraser - 通讯作者:
Abigail Fraser
Kate Birnie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kate Birnie', 18)}}的其他基金
Understanding the link between kidney health and pregnancy outcomes
了解肾脏健康与妊娠结局之间的联系
- 批准号:
MR/Y011139/1 - 财政年份:2024
- 资助金额:
$ 35.64万 - 项目类别:
Fellowship
相似国自然基金
慢性炎症诱发骨丢失的机制及外泌体靶向治疗策略研究
- 批准号:82370889
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
SAMMSON-CARF-p53信号轴调控黑色素瘤适应性耐药的机制研究
- 批准号:32000541
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
CDKL3在肾细胞癌中功能与分子机制的研究及小分子抑制剂的合成与表征
- 批准号:31970721
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
铁氧还蛋白还原酶FDXR促进雌激素受体阳性乳腺癌内分泌治疗耐药的分子机制研究
- 批准号:31970737
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
NLK磷酸化IRF2BP2对PD-L1表达调控的研究
- 批准号:31900554
- 批准年份:2019
- 资助金额:15.0 万元
- 项目类别:青年科学基金项目
基于内质网应激-自噬反应研究“脾主肌肉”理论下推拿脾经治疗骨骼肌损伤的作用机制
- 批准号:81904317
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
利用纳米金-核酸复合物阻断乏氧信号通路和抑制肿瘤细胞增殖的研究
- 批准号:31100716
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
- 批准号:81171370
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
以IGF2/IGF1R与SYT/SSX1为靶点治疗滑膜肉瘤的实验研究
- 批准号:81102033
- 批准年份:2011
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
miR-30c对胃癌EGFR信号通路的调控作用及其机制研究
- 批准号:81101715
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
- 批准号:
10723233 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Interleukin-1 Receptor Modulating Therapy for Treating Macular Degeneration
用于治疗黄斑变性的 IL-1 受体调节疗法
- 批准号:
478746 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Operating Grants
Treating non-small cell lung tumors with a novel inhaled dry powder chemotherapeutic formulation
用新型吸入干粉化疗制剂治疗非小细胞肺肿瘤
- 批准号:
10696996 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis
治疗类风湿关节炎的新型免疫导向生物疗法
- 批准号:
10760183 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
An Aptamer-directed IgG1-Fc Drug Conjugate (AFDC) for Treating Pancreatic Cancer
用于治疗胰腺癌的适体导向 IgG1-Fc 药物偶联物 (AFDC)
- 批准号:
10761053 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Membrane repair as a therapeutic intervention for treating Becker Muscular Dystrophy
膜修复作为治疗贝克尔肌营养不良症的治疗干预措施
- 批准号:
10761285 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection
治疗无症状 CMV 复制对 HIV 感染治疗者心血管风险的影响
- 批准号:
10715847 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Novel approach of targeting AT-rich S/MAR regions for treating therapy resistant breast cancers
靶向富含 AT 的 S/MAR 区域治疗耐药性乳腺癌的新方法
- 批准号:
10744563 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
R21 MPI microRNA 定向疗法治疗早期胰腺癌
- 批准号:
10577609 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别:
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
开发用于治疗胶质母细胞瘤的有效雌激素受体β激动剂
- 批准号:
10594832 - 财政年份:2023
- 资助金额:
$ 35.64万 - 项目类别: